Insider Selling: Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Sells 11,250 Shares of Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 11,250 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $41.27, for a total transaction of $464,287.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Wednesday, June 19th, Thomas Patrick Kelly sold 177 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $25.00, for a total transaction of $4,425.00.
  • On Monday, June 3rd, Thomas Patrick Kelly sold 2,100 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00.
  • On Wednesday, May 22nd, Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $25.06, for a total transaction of $36,913.38.

Shares of NASDAQ:DCPH traded up $15.95 during trading on Tuesday, reaching $35.90. The company had a trading volume of 10,854,326 shares, compared to its average volume of 291,452. The company has a fifty day moving average price of $22.57. The stock has a market cap of $1.44 billion, a PE ratio of -12.73 and a beta of 2.34. Deciphera Pharmaceuticals Inc has a 12 month low of $18.55 and a 12 month high of $42.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.26 and a quick ratio of 7.26.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last issued its quarterly earnings results on Friday, August 2nd. The company reported ($0.56) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.12) by $0.56. The company had revenue of $25.00 million during the quarter, compared to the consensus estimate of $20.00 million. As a group, equities research analysts predict that Deciphera Pharmaceuticals Inc will post -4.29 EPS for the current year.

Large investors have recently modified their holdings of the company. Bank of Montreal Can bought a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter worth $28,000. BNP Paribas Arbitrage SA increased its holdings in shares of Deciphera Pharmaceuticals by 61,033.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,834 shares of the company’s stock worth $43,000 after buying an additional 1,831 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Deciphera Pharmaceuticals by 89.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the company’s stock worth $95,000 after buying an additional 1,913 shares during the last quarter. Virtus ETF Advisers LLC increased its holdings in shares of Deciphera Pharmaceuticals by 17.7% in the 2nd quarter. Virtus ETF Advisers LLC now owns 12,449 shares of the company’s stock worth $281,000 after buying an additional 1,871 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new position in shares of Deciphera Pharmaceuticals in the 2nd quarter worth $374,000. 59.10% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently weighed in on the stock. Deutsche Bank assumed coverage on shares of Deciphera Pharmaceuticals in a report on Thursday, July 18th. They set a “buy” rating and a $42.00 target price on the stock. BidaskClub raised shares of Deciphera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 2nd. Zacks Investment Research raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating and set a $26.00 target price on the stock in a report on Monday, August 5th. Piper Jaffray Companies upped their target price on shares of Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, June 3rd. They noted that the move was a valuation call. Finally, ValuEngine raised shares of Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $43.67.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Further Reading: What is the Difference Between Common Shares and Convertible Shares?

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.